" class="no-js "lang="en-US"> Thomas Clozel - Medtech Alert
Saturday, September 30, 2023

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Thomas Clozel

Thomas Clozel

About Thomas Clozel

I am a 38 years old creative and dynamic Medical Doctor, former Assistant Professor in clinical hematology, whose work is focused on integrating AI and system biology to enable breakthrough medical moments

Related Story

Artificial Intelligence

 Owkin

Owkin, the Francis Crick Institute and the Royal Marsden NHS Foundation Trust to Use AI to Research Kidney Cancer Evolution

July 22 2022

Owkin is partnering with scientists from the Francis Crick Institute and The Royal Marsden NHS […]

Appointments

 Owkin Announces New Scientific Advisory Board Chaired by World-leading Precision Oncologist | Pharmtech Focus

Owkin Announces New Scientific Advisory Board Chaired by World-leading Precision Oncologist

March 25 2022

French-American AI for medical research startup Owkin today appointed ten advisors to its Scientific Advisory […]

Artificial Intelligence

 Sanofi Invests $180 Million Equity in Owkin ’s Artificial Intelligence and Federated Learning to Advance Oncology Pipeline | Pharmtech Focus

Sanofi Invests $180 Million Equity in Owkin ’s Artificial Intelligence and Federated Learning to Advance Oncology Pipeline

November 19 2021

Sanofi announced today an equity investment of $180 million and a new strategic collaboration with […]